ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Aberrant epigenetic regulation of FZD3 by TET2 is involved in ovarian cancer cell resistance to cisplatin

Zhu, Li; Zhou, Qian*1
JOURNAL OF CHEMOTHERAPY2023-6-2DOI: 10.1080/1120009X.2023.2219920
7阅读
引用收藏
分享

摘要

A major challenge in platinum-based cancer therapy, including cisplatin (DDP), is the clinical management of chemo-resistant tumours, which have unknown pathogenesis at the level of epigenetic mechanism. To identify potential resistance mechanisms, we integrated ovarian cancers (OC)-related GEO database retrieval and prognostic analyses. The results of bioinformatics prediction showed that frizzled class receptor 3 (FZD3) was a DDP-associated gene and closely related to the prognosis of OC. DDP resistance in OC inhibited FZD3 expression. FZD3 reduced DDP resistance in OC cells, increased the inhibitory effect of DDP on the growth and aggressiveness of DDP-resistant cells, and promoted apoptosis and DNA damage. TET2 was reduced in OC. TET2 promoted the transcription of FZD3 through DNA hydroxymethylation. TET2 sensitized the drug-resistant cells to DDP in vitro and in vivo, and the ameliorating effect of TET2 on drug resistance was significantly reversed after the inhibition of FZD3. Our findings reveal a previously unknown epigenetic axis TET2/FZD3 suppression as a potential resistance mechanism to DDP in OC.

学科与关键词

关键词
TET2FZD3ovarian cancercisplatin resistanceDNA hydroxymethylation
相关
加载中…
  • TAZ Regulates the Cisplatin Resistance of Epithelial Ovarian Cancer Cells via the ANGPTL4/SOX2 Axis
    Li, Caihong*; Wang, Qin; Luo, Youzhen; Xiang, JuanAnalytical Cellular Pathology-Cellular Oncology, 2022, 2022: 5632164.被引 1
  • Candidate DNA methylation drivers of acquired cisplatin resistance in ovarian cancer identified by methylome and expression profiling
    C Zeller; W Dai; N L Steele; A Siddiq; A J Walley; C S M Wilhelm-Benartzi; S Rizzo; A van der Zee; J A Plumb; R BrownOncogene, 2012, 31(Suppl 2).
  • FBP1 knockdown decreases ovarian cancer formation and cisplatin resistance through EZH2-mediated H3K27me3
    Xiong, Xifeng; Lai, Xudong; Zhang, Jinli; Meng, Qingqi; Wang, Pengzhen; Qin, Shengnan; Liu, Wei; Wang, Yongxuan; Yao, Zhuo; Wang, Di; Li, Xiaojian*; Liu, Zhihe*; Miao, Haixiong*Bioscience Reports, 2022, 42(9): BSR20221002.被引 2
查看全部 →

发表信息

论文状态
公开发表
期刊
JOURNAL OF CHEMOTHERAPY
发表日期
2023-06-02
DOI
10.1080/1120009X.2023.2219920
语言
ENGLISH
成果收录
SCIE

作者

  • Z

    Zhu, Li (第一作者)

    china three gorges univ

  • Z

    Zhou, Qian (通讯)

    1 · three gorges univ

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417